Atogepant Patent Expiry
Atogepant, a medication for migraine prevention, has a patent landscape that impacts its market availability and the potential for generic versions.
When Does the Atogepant Patent Expire?
The primary patent protecting atogepant, U.S. Patent No. 10,299,910, is set to expire in 2037 [1]. This patent covers the compound itself and its use in treating migraines.
What Does This Patent Cover?
The U.S. Patent No. 10,299,910 specifically claims atogepant and methods for treating migraine headaches. This protection is crucial for the drug's developer, as it grants them exclusive rights to market and sell the drug until the patent term concludes [1].
Who Developed Atogepant?
Atogepant was developed by AbbVie [2]. It is marketed under the brand name Qulipta [3].
What is Atogepant Used For?
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of episodic migraine in adults [3].
Are There Other Patents on Atogepant?
Beyond the primary compound patent, there may be other patents related to atogepant, such as those covering specific formulations, manufacturing processes, or methods of use. These secondary patents can sometimes extend market exclusivity beyond the expiry of the main compound patent. Information on specific secondary patents and their expiry dates can be found through patent databases [1].
Can Generic Atogepant Be Available Before Patent Expiry?
Generally, generic versions of a drug cannot be marketed until the relevant patents expire, or if those patents are successfully challenged. Companies seeking to introduce a generic version often file Abbreviated New Drug Applications (ANDAs) with regulatory bodies like the U.S. Food and Drug Administration (FDA). The FDA will not approve an ANDA if the proposed generic infringes on existing, valid patents [1].
How Are Drug Patents Challenged?
Companies can challenge drug patents through various legal mechanisms. This often involves demonstrating that the patent is invalid, for example, due to prior art that was not considered by the patent office, or that their product does not infringe the patent claims [1]. Such challenges can lead to earlier market entry for generic competitors.
What is the Significance of Atogepant's Patent for Patients?
The patent protection for atogepant means that for the duration of the patent, AbbVie will be the sole provider of the branded drug. This exclusivity typically allows for higher pricing. Once the patent expires and generic versions become available, competition can drive down prices, making the medication more accessible to patients [1].
Sources:
1. DrugPatentWatch.com
2. AbbVie Inc.
3. Qulipta Official Website